# Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer

> **NCT02204059** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 9 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** hMAb BIWA 4

## Key facts

- **NCT ID:** NCT02204059
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2001-02
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2014-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204059, "Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02204059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*